Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody and a novel immune-checkpoint inhibitor for cancer treatment. Produced by recombinant DNA technology in Chinese Hamster Ovary (CHO) cell suspension culture, durvalumab is a programmed death-ligand 1 (PD-L1) blocking antibody that works to promote normal immune responses that attack tum...
Durvalumab is indicated for the treatment of adults with the following conditions:
University of Alabama at Birmingham, Birmingham, Alabama, United States
Chinese PLA General Hospital, Beijing, Beijing, China
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Vall d'Hebron Institute of Oncology, Barcelona, Spain
Orlando Health Cancer Institute, Orlando, Florida, United States
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
FirstHealth of the Carolinas, Pinehurst, North Carolina, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.